XiaoningSun

Associate

Singapur + 65.6233.5500

Contacto:

Compartir

Xiaoning Sun represents financial institutions and sponsors/borrowers on a broad range of domestic and cross-border debt transactions, including club and syndicated loans; project, acquisition, and asset financings; and debt restructurings.

Prior to joining Jones Day in 2023, Xiaoning practiced at a top-tier international law firm in Singapore where she advised clients on a range of debt-related transactions, including project financing, asset financing, and capital call financing.

Experiencia

  • Coronado Global Resources completes $400 million Senior Secured Notes offeringJones Day advised Coronado Global Resources Inc. (ASX: CRN) (“Coronado”), a global producer, marketer, and exporter of a full range of metallurgical coal products, in connection with an offering by one of its wholly-owned subsidiaries of US$400 million aggregate principal amount of 9.250% Senior Secured Notes due 2029 in a Rule 144A and Regulation S offering.
  • Five9 acquires AcqueonJones Day advised Five9, Inc. in its acquisition of Acqueon, a pioneering real-time revenue execution platform, realizing Five9's ambition to become the orchestration engine for every interaction across the entire customer journey, including marketing, e-commerce, sales and customer service through AI-driven, omnichannel proactive customer engagement.
  • Mayur Resources obtains US$155 million financing to complete Central Lime ProjectJones Day advised Mayur Resources Limited on the debt financing agreements with Appian Capital Advisory LLP and combined equity funding from Vision Blue Resources, a clean energy battery metals transition investment vehicle led by Sir Mick Davis, for a total of approximately US$155 million to complete the Central Lime Project.
  • Timken acquires Des-CaseJones Day advised The Timken Company in the acquisition of Des-Case Corp., a Nashville, Tenn.-based manufacturer of specialty filtration products for industrial lubricants.
  • Junshi grants exclusive rights to Dr. Reddy's for toripalimab cancer treatmentJones Day represented Shanghai Junshi Biosciences Co., Ltd. ("Junshi") in its grant of exclusive rights related to the development and commercialization of toripalimab, an anti-PD1 monoclonal antibody, to Dr. Reddy's Laboratories for the territory of Latin America, India, South Africa, and an option to expand the territory to include Australia and New Zealand and potential other countries.
    •

    July 2024 White Paper

    APAC ESG Update | Spring Quarter 2024

    February 2024 White Paper

    APAC ESG Update | Winter Quarter 2023–24

    Antes del envío, por favor tenga en cuenta:

    la información contenida en www.jonesday.com es para uso general y no constituye asesoramiento legal. El envío y recepción de este correo electrónico no pretenden crear una relación abogado-cliente. La información que envíe a cualquier persona de nuestra Firma no tendrá carácter confidencial o privilegiado excepto en el caso de que estemos actúando en su representación. Si envía este correo electrónico, confirma que ha leído y comprendido este aviso.